Pexastimogene Devacirepvec (Pexa Vec)

BIOLOGICAL2 trials

Sponsors

SillaJen, Inc., Transgene

Conditions

Hepatocellular Carcinoma (HCC)

Phase 1

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

TerminatedNCT03071094

TransgeneHepatocellular Carcinoma (HCC)

Start: 2017-07-27End: 2021-02-03Updated: 2021-11-19

Phase 3

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

CompletedNCT02562755

SillaJen, Inc.Hepatocellular Carcinoma (HCC)

Start: 2015-10-01End: 2020-07-01Updated: 2026-06-08

Related Papers

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity.

Journal of Clinical Oncology2018-05-208 citations

PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.

Journal of Clinical Oncology2016-05-2040 citations